Renée JG Arnold is currently President & CEO, Arnold Consultancy & Technology, LLC, where she oversees outcomes research and develops affiliated software for pharmaceutical and government programs. Her special interest in evidence-based health derives from her research that deals with use of technology to collect and/or model real-world data for use in rational decision-making by healthcare practitioners and policy makers. She is also Adjunct Professor, Master of Public Health program, Department of Environmental Medicine and Public Health at the Icahn School of Medicine at Mount Sinai, New York, New York, where she has developed and teaches the pharmacoeconomics coursework. Dr. Arnold completed her undergraduate training at the University of Maryland and received her Doctor of Pharmacy degree from the University of Southern California in Los Angeles. She also completed a post-doctoral residency at University Hospital in San Diego/University of California at San Francisco School of Pharmacy. Dr. Arnold is a founding member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and is the Chair of multiple special interest groups (SIGS) there including, most recently, the Open Source Model SIG. Dr. Arnold is an author of numerous articles, book chapters and books in the areas of pharmacology, pharmacoeconomics and

Dr. Charles D. Buchen is a seasoned biopharmaceutical executive with over 15 years of experience in business development, strategic transactions, and drug development across oncology and rare diseases. He currently serves as a consultant and advisor to multiple biotechnology companies while maintaining active involvement in clinical research and translational medicine.

Jennifer Butler is a distinguished global commercial executive and strategic leader with nearly 20 years of experience transforming biotechnology companies from early development through commercial success. She currently serves as Montgomery County's first "Executive in Residence," a pioneering role created through a collaboration between Montgomery County and BioHealth Innovation, Inc. (BHI) to provide technical assistance to local biotech startups.

Joseph DiCesare is a distinguished pharmaceutical industry executive with over 30 years of experience in health economics and outcomes research (HEOR), real-world evidence (RWE), and strategic planning. Throughout his career, he has held leadership positions at major pharmaceutical companies and consulting organizations, establishing himself as a recognized expert in demonstrating the value of pharmaceutical innovations through rigorous economic analysis and evidence generation.

Luis T. Gutierrez, Jr. is a distinguished business leader and entrepreneur with over 25 years of experience bringing new medical technologies to market and helping start-up companies transition into successful commercial enterprises. With a proven track record of driving revenue and profit growth through innovative life science products and services, he currently serves in multiple strategic advisory roles while maintaining active involvement in company building and technology commercialization.

Dr. Kevin N. Heller is a distinguished physician-scientist and drug development executive with over 20 years of experience in oncology research and biopharmaceutical development. His career spans the complete drug development lifecycle from discovery through commercialization, with particular expertise in immuno-oncology, precision medicine, and regulatory strategy across academia and industry.

Dr. John K. Hsu is a distinguished intellectual property attorney and patent litigator with over twenty years of specialized experience in complex pharmaceutical and technology litigation. With a unique combination of advanced scientific training and extensive legal expertise, he has successfully represented clients in more than sixty high-stakes patent, trademark, and trade secret cases across diverse industries, with particular focus on pharmaceutical drugs, medical devices, computer software, and food processing technology.

Dr. Diane M. Ignar is a distinguished pharmaceutical executive and strategic advisor with over 25 years of comprehensive experience spanning the complete biopharmaceutical value chain from discovery research through commercialization. Her extensive expertise encompasses therapeutic development, business partnerships, emerging markets strategy, and technology innovation across multiple therapeutic areas including neuropharmacology, metabolic diseases, respiratory and allergic diseases, rare diseases, and oncology.

Jonathan B. Kay, MPP, is an Executive-in-Residence (EIR) at BioHealth Innovation, where he provides strategic technical assistance to biotech and life sciences startups to advance technological innovation and drive high-value job creation in the regional ecosystem. As a trusted advisor to the life sciences industry, he brings comprehensive expertise across biotech, pharmaceuticals, medical devices, diagnostics, vaccines, and digital health, including artificial intelligence applications in healthcare.

Douglas Liu is a distinguished business leader and operations executive with over 40 years of comprehensive experience in the biotechnology industry, specializing in manufacturing, quality assurance, regulatory affairs, and global operations management. His career spans the complete biotechnology value chain from early-stage development through commercial manufacturing, with particular expertise in molecular diagnostics, clinical research, and international business development.

Dr. Kimberly E. Martin is a distinguished scientific and clinical affairs executive with over 25 years of comprehensive experience bringing drugs and medical devices to market. As an Entrepreneur-in-Residence (EIR) and advisor to the National Institutes of Health (NIH), she combines deep technical expertise in clinical trial design and regulatory strategy with innovative leadership in pharmaceutical and medical device development across multiple therapeutic areas.

Dr. Kuldeep Neote is a seasoned biotechnology executive and venture capital professional with over 25 years of experience in external innovation, business development, and strategic partnerships across the life sciences industry. His career encompasses roles at leading pharmaceutical companies, innovative biotech ventures, and investment organizations, with particular expertise in immunology, oncology, and gene therapy development.